This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Abizaid, A. Articles by Sousa, J. E. Search for Related Content PubMed PubMed Citation Articles by Abizaid, A. Articles by Sousa, J. E.

EXPRESS PUBLICATION

First human experience with the 17-beta-estradiol–eluting stent

The estrogen and stents to eliminate restenosis (EASTER) trial

Alexandre Abizaid, MD, PhD^*,*, Mariano Albertal, MD, PhD^*, Marco A. Costa, MD, PhD, Andrea S. Abizaid, MD, PhD^*, Rodolfo Staico, MD^*, Fausto Feres, MD, PhD^*, Luiz A. Mattos, MD, PhD^*, Amanda G. M. R. Sousa, MD, PhD^*, Jeffrey Moses, MD, Nicholas Kipshidize, MD, Gary S. Roubin, MD, Roxana Mehran, MD, Gishel New, MD^||, Martin B. Leon, MD and J. Eduardo Sousa, MD, PhD^*

^* Institute Dante Pazzanese of Cardiology, São Paulo, Brazil
University of Florida-Shands, Jacksonville, Florida, USA
Lenox Hill Hospital, New York, New York, USA
Cardiovascular Research Foundation, New York, New York, USA
^|| Box Hill Hospital, Melbourne, Australia

Manuscript received August 5, 2003; revised manuscript received December 4, 2003, accepted December 9, 2003.

^* Reprint requests and correspondence: Dr. Alexandre Abizaid, Av. Dr. Dante Pazzanese 500, Ibirapuera, São Paulo, SP, Brazil, CEP: 04012-909.
aabizaid{at}uol.com.br

OBJECTIVES: The purpose of the study was to examine the safety and efficacy of 17-beta-estradiol–eluting stent implantation on coronary de novo lesions.

BACKGROUND: Recent animal data indicate that local delivery of 17-beta-estradiol promotes re-endothelialization, inhibits cell migration and proliferation, and prevents restenosis.

METHODS: A total of 30 consecutive patients underwent 17-beta-estradiol–eluting BiodVysio (Biocompatibles Ltd., London, United Kingdom) stent implantation for the treatment of coronary de novo lesions. Clinical, angiographic, and intravascular ultrasound (IVUS) analysis was performed at six-month follow-up.

RESULTS: All stents were successfully deployed and patients were discharged home without clinical events. A total of two patients exceeded 50% intra-stent narrowing by angiography, whereas no patients experienced edge restenosis. One patient had focal intra-stent restenosis (60% diameter stenosis) with no symptoms and negative stress test, whereas the other patient had diffuse restenosis, requiring target vessel revascularization. No other patient experienced any major adverse cardiac event. Follow-up IVUS revealed a neointimal hyperplasia volume of 32.3 ± 16.4 mm³, whereas the stent volume was 143.7 ± 43.7 mm³, resulting in a neointimal volume obstruction of 23.5 ± 12.5%. None of the patients had 50% volume obstruction by IVUS.

CONCLUSIONS: Implantation of 17-beta-estradiol–eluted BiodVysio stents appears feasible and safe, showing low rates of binary restenosis and revascularization. These results warrant further confirmation with a large, randomized multicenter trial.

Abbreviations and Acronyms   IVUS = intravascular ultrasound   PC = phosphorylcholine   QCA = quantitative coronary angiography

This article has been cited by other articles:

				P. Jimenez-Quevedo, N. Suzuki, C. Corros, C. Ferrer, D. J. Angiolillo, F. Alfonso, R. Hernandez-Antolin, C. Banuelos, J. Escaned, C. Fernandez, et al. Vessel Shrinkage as a Sign of Atherosclerosis Progression in Type 2 Diabetes: A Serial Intravascular Ultrasound Analysis Diabetes, January 1, 2009; 58(1): 209 - 214. [Abstract] [Full Text] [PDF]

				I. C Villar, A. J Hobbs, and A. Ahluwalia Sex differences in vascular function: implication of endothelium-derived hyperpolarizing factor J. Endocrinol., June 1, 2008; 197(3): 447 - 462. [Abstract] [Full Text] [PDF]

				C. Filipe, L. Lam Shang Leen, L. Brouchet, A. Billon, V. Benouaich, V. Fontaine, P. Gourdy, F. Lenfant, J.-F. Arnal, A.-P. Gadeau, et al. Estradiol accelerates endothelial healing through the retrograde commitment of uninjured endothelium Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2822 - H2830. [Abstract] [Full Text] [PDF]

				T. Adriaenssens, J. Mehilli, R. Wessely, G. Ndrepepa, M. Seyfarth, A. Wieczorek, B. Blaich, R. Iijima, J. Pache, A. Kastrati, et al. Does Addition of Estradiol Improve the Efficacy of a Rapamycin-Eluting Stent?: Results of the ISAR-PEACE Randomized Trial J. Am. Coll. Cardiol., March 27, 2007; 49(12): 1265 - 1271. [Abstract] [Full Text] [PDF]

				Y. D. Krom, N. M.M. Pires, J. W. Jukema, M. R. de Vries, R. R. Frants, L. M. Havekes, K. W. van Dijk, and P. H.A. Quax Inhibition of neointima formation by local delivery of estrogen receptor alpha and beta specific agonists Cardiovasc Res, January 1, 2007; 73(1): 217 - 226. [Abstract] [Full Text] [PDF]

				H. Futamatsu, M. Sabate, D. J. Angiolillo, P. Jimenez-Quevedo, C. Corros, K. Morikawa-Futamatsu, F. Alfonso, J. Jiang, P. Cervinka, R. Hernandez-Antolin, et al. Characterization of Plaque Prolapse After Drug-Eluting Stent Implantation in Diabetic Patients: A Three-Dimensional Volumetric Intravascular Ultrasound Outcome Study J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1139 - 1145. [Abstract] [Full Text] [PDF]

				P. Collins, M. Flather, B. Lees, R. Mister, A. J. Proudler, J. C. Stevenson, and on behalf of the WHISP (Women's Hormone Interventi Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study Eur. Heart J., September 1, 2006; 27(17): 2046 - 2053. [Abstract] [Full Text] [PDF]

				P. Jimenez-Quevedo, M. Sabate, D. J. Angiolillo, M. A. Costa, F. Alfonso, J. A. Gomez-Hospital, R. Hernandez-Antolin, C. Banuelos, J. Goicolea, F. Fernandez-Aviles, et al. Vascular Effects of Sirolimus-Eluting Versus Bare-Metal Stents in Diabetic Patients: Three-Dimensional Ultrasound Results of the Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial J. Am. Coll. Cardiol., June 6, 2006; 47(11): 2172 - 2179. [Abstract] [Full Text] [PDF]

				C.-H. Lee, H.-C. Tan, and Y.-T. Lim Update on Drug-Eluting Stents for Prevention of Restenosis Asian Cardiovasc Thorac Ann, February 1, 2006; 14(1): 75 - 82. [Abstract] [Full Text] [PDF]

				B. Jaschke, C. Michaelis, S. Milz, M. Vogeser, T. Mund, L. Hengst, A. Kastrati, A. Schomig, and R. Wessely Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform Cardiovasc Res, December 1, 2005; 68(3): 483 - 492. [Abstract] [Full Text] [PDF]

				J. E. Sousa, M. A. Costa, A. Abizaid, F. Feres, A. C. Seixas, L. F. Tanajura, L. A. Mattos, R. Falotico, J. Jaeger, J. J. Popma, et al. Four-Year Angiographic and Intravascular Ultrasound Follow-Up of Patients Treated With Sirolimus-Eluting Stents Circulation, May 10, 2005; 111(18): 2326 - 2329. [Abstract] [Full Text] [PDF]

				M. A. Costa and D. I. Simon Molecular Basis of Restenosis and Drug-Eluting Stents Circulation, May 3, 2005; 111(17): 2257 - 2273. [Full Text] [PDF]

				W. W. O'Neill, S. R. Dixon, and C. L. Grines The year in interventional cardiology J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1117 - 1134. [Full Text] [PDF]

				J. F. Reckelhoff Sex Steroids, Cardiovascular Disease, and Hypertension: Unanswered Questions and Some Speculations Hypertension, February 1, 2005; 45(2): 170 - 174. [Full Text] [PDF]